Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Cancer is the fastest growing sector, North America is the largest market

The Global Viral Vector and Plasmid DNA Manufacturing Market is projected to expand from USD 7.17 Billion in 2025 to USD 13.43 Billion by 2031, achieving an 11.03% CAGR. This sector specializes in producing biological vehicles and genetic templates essential for gene therapies and vaccines. Its growth is primarily driven by the rising incidence of chronic and genetic disorders, creating demand for advanced therapeutic solutions, and a significant pipeline of therapeutic candidates in clinical development, with over 3,200 gene, cell, and RNA therapy trials active globally in 2025, as per the American Society of Gene & Cell Therapy. However, a key obstacle to market growth is the technical challenge of scaling production to commercial volumes, where manufacturers face difficulties maintaining consistent quality and high yields when moving from lab to mass production. This bottleneck leads to supply shortages and elevated costs, hindering treatment availability and overall market expansion.

Market Drivers

The Global Viral Vector and Plasmid DNA Manufacturing Market is primarily driven by the rapid expansion of gene and cell therapy clinical pipelines. As therapeutic candidates advance through trials toward commercialization, the need for high-quality, GMP-grade viral vectors escalates. This demand is bolstered by significant capital infusions, with sector investments reaching $15.2 billion in 2025 - a 30% year-over-year increase - according to the Alliance for Regenerative Medicine. Such financial support has contributed to regulatory triumphs, including seven new cell and gene therapy product approvals in the U.S.

during the preceding year, as reported by the International Society for Cell & Gene Therapy, thereby generating immediate commercial need for scalable vector production. A secondary, yet crucial, driver is the growing dependence on Contract Development and Manufacturing Organizations (CDMOs). Many biopharmaceutical firms, especially smaller and mid-sized ones, outsource complex viral vector production due to a lack of specialized infrastructure and expertise. This strategy helps them mitigate technical risks and accelerate market entry, a trend exemplified by Oxford Biomedica's 44% revenue increase to £128.8 million, largely propelled by strong demand for lentiviral vector manufacturing services, highlighting CDMOs' essential role in commercializing clinical innovations.

Market Challenges

The foremost challenge impeding the Global Viral Vector and Plasmid DNA Manufacturing Market is the technical complexity involved in scaling production to commercial levels. Unlike conventional pharmaceuticals, viral vectors and plasmid DNA production relies on intricate biological processes susceptible to slight environmental changes. Consequently, manufacturers often face substantial reductions in yield and consistency when attempting to transition from laboratory efficacy to mass production.

This critical manufacturing bottleneck limits the supply of vital genetic material and keeps production costs excessively high for many developers. Such production constraints directly undermine the commercial viability of numerous potential therapies, leading to a market heavily concentrated on a few successful treatments rather than a wide array of accessible medicines. Data from the Alliance for Regenerative Medicine in 2025 revealed that nearly 75 percent of global advanced therapy revenue came from fewer than ten commercialized products, clearly demonstrating how scalability hurdles prevent the sector from fully leveraging its extensive pipeline of therapeutic candidates.

Market Trends

To address persistent scalability and quality control issues, the market is undergoing fundamental shifts through the integration of automated and closed-system manufacturing. This involves moving from manual, open operations to fully enclosed, robotic platforms, which substantially lowers contamination risks and enhances batch-to-batch consistency. This technological advancement is supported by significant investments in digitized and robotic facilities designed to industrialize complex viral vector processes, such as Novartis's EUR 40 million fully automated VIFA One production facility in Slovenia, launched in February 2025, utilizing advanced robotics across all stages.

Concurrently, a crucial trend is the shift toward enzymatic and synthetic DNA production, moving away from cell-based plasmid fermentation to cleaner, cell-free synthesis methods. This approach mitigates biological variability and long lead times inherent in traditional bacterial cultures, providing a streamlined pathway for producing high-purity genetic starting materials. The growing adoption of these synthetic templates is reflected in the strong financial performance of specialized technology providers, with 4basebio reporting £1.2 million in revenue for its synthetic DNA solutions in the first half of 2025, surpassing its previous full year's total by 25%, as per its September 2025 half-year report.

Key Market Players

• Oxford Biomedica PLC
• Cognate BioServices Inc.
• Cell and Gene Therapy Catapult Ltd.
• FinVector Vision Therapies
• Fujifilm Holdings Corporation
• SIRION Biotech GmbH
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Uniqure NV
• Catalent Inc.

Report Scope

In this report, the Global Viral Vector and Plasmid DNA Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viral Vector and Plasmid DNA Manufacturing Market, by Product Type:

• Plasmid DNA
• Viral Vector
• Non-viral Vector

Viral Vector and Plasmid DNA Manufacturing Market, by Application:

• Cancer
• Genetic Disorder
• Infectious Disease
• Others

Viral Vector and Plasmid DNA Manufacturing Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector and Plasmid DNA Manufacturing Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.